Stakeholder Perspectives of Australia’s National HPV Vaccination Program

Author:

Swift Caitlin,Dey Aditi,Rashid HarunorORCID,Clark Katrina,Manocha Ramesh,Brotherton Julia,Beard Frank

Abstract

Australia has been a world leader in human papillomavirus (HPV) vaccination and was the first country to implement a fully funded national HPV vaccination program, from 2007 for girls and 2013 for boys. In 2018 the program changed from a 4-valent to 9-valent HPV vaccine and a 3-dose to 2-dose standard schedule. We assessed stakeholder perspectives on factors influencing program outcomes and impact as part of a comprehensive program evaluation. In late 2019 and early 2020, we conducted 26 interviews with 42 key stakeholder participants and received 1513 survey responses from stakeholders including general practice staff and school-based nurse immunisers. Findings included that the 2-dose schedule is better accepted by schools and students and has reduced program cost and resource requirements. However, course completion rates have not increased as much as anticipated due to the 6–12 month dosing interval and reduced opportunities for school-based catch-up vaccination. Major reported barriers to increased vaccine coverage were absenteeism and consent form return. Vaccine hesitancy is not currently a major issue but remains a potential threat to the program. While Australia’s HPV vaccination program is perceived as highly successful, measures to further enhance the program’s impact and mitigate potential threats are important.

Funder

NCIRS and the Australian Government Department of Health and Aged Care

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference44 articles.

1. Worldwide burden of cancer attributable to HPV by site, country and HPV type;Int. J. Cancer,2017

2. Understanding Genital Warts: Epidemiology, Pathogenesis, and Burden of Disease of Human Papillomavirus;J. Cutan. Med. Surg.,2013

3. Recurrent respiratory papillomatosis: A state-of-the-art review;Respir. Med.,2017

4. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;CA Cancer J. Clin.,2021

5. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis;Lancet Glob. Health,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3